Knee cartilage repair for teens: study pulled before it began
NCT ID NCT05391841
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study planned to test NOVOCART Inject, a treatment using a patient's own cartilage cells, for repairing knee cartilage defects in teenagers whose bones had finished growing. The goal was to see if it improved knee function and pain. However, the study was withdrawn before enrolling any participants, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- NOVOCART Inject (a treatment using the patient's own cartilage cells to repair knee damage)
- What this could lead to
- If it had worked, this could have pointed toward a way to repair knee cartilage in teenagers, potentially delaying or avoiding knee replacement later in life.
- What could go wrong
- The study was withdrawn before any patients were enrolled, so no results are available. Even if it had proceeded, it was a small, single-arm study with no comparison group, making it hard to know if the treatment truly helps.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Expected to start
-
May 2025
An estimate. Start dates often move.
- Expected to finish
-
May 2032
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Pediatric patients (\< 18 years of age) with closed epiphyses who suffer from a full-thickness cartilage defect of the knee caused by acute or repetitive trauma or by osteochondrosis dissecans and who are scheduled for treatment with NOVOCART Inject SmPC, where the therapeutic indications, contraindications, special warnings and precautions for use are listed in detail. The decision to treat patients with NOVOCART Inject must be made independently from the patient's participation in the study.
- Ages
-
Up to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Pediatric patients (\< 18 years of age at implantation) * Closure of the epiphysis adjacent to the biopsy harvest site or the defect to be treated confirmed by an adequate imaging modality * Localized full-thickness cartilage defect (ICRS grade III or IV) of the knee * Medicinal indication for NOVOCART® Inject treatment Exclusion Criteria: see NOVOCART Inject SmPC
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cartilage disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Klinikum rechts der Isar, Technische Universität München
München, 81675, Germany
-
OCM Klinik GmbH München
München, 81369, Germany
-
St. Josefs-Hospital Cloppenburg gemeinnützige GmbH
Cloppenburg, 49661, Germany
-
Universitätsklinikum Freiburg
Freiburg im Breisgau, 79119, Germany
-
Universitätsklinikum Regensburg
Regensburg, 93053, Germany
-
Universitätsklinikum Tübingen
Tübingen, 72076, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.